American study reveals a new sprite of the nose to treat depression

Health and Medical

A team of American researchers – in their latest study – has developed a new nasal spray for the treatment of depression patients.

The current study, published in the American Journal of Psychiatry, is one of the main findings that led to the recent approval by the Food and Drug Administration of the nasal sphincter aspirin to be taken alongside oral antidepressants for use in people Suffering from depression resistant to treatment.

"The new mechanism of escitamine, in addition to the speed of utility, underscores the importance of this development to patients who are difficult to treat from depression," said Dr. Michael Thaies, a professor at the University of Pennsylvania in the United States."He said.

The study was conducted in 39 centers for patients from August 2015 to June 2017, involving nearly 200 adults with moderate to severe depression and a history of non-response to antidepressants. During the study, participants were randomized to one of two groups, One combination of their current treatment has been switched to aspirin nasal sprays, or 84 milligrams twice a week plus newly started antidepressants.

The study said the other group had been transformed from current therapy to nasal nasal spray in conjunction with new antidepressants.

The improvement in depression among those in the scetamin group was significantly higher than the placebo group on day 28, the study said. Similar improvements were seen in previous points of time. The negative events in the ischemin group generally occurred shortly after the drug was taken and resolved after an hour and a half while the patients were in the clinic. The most common side effects included dislocation, nausea, dizziness, indigestion ) And dizziness, 7% of patients in the scetamine group stopped studying due to side effects.

Related topics

(tagsToTranslate) Antidepressants (t) Sprays of the nose (t) Psychiatry